Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
There is considerable overlap in the clinical presentations of apathy and depression. However, differential diagnosis between apathy and other psychiatric conditions, including depression and dementia, is important. In this report, we present the case of a 67-year-old woman with a history of receiving selective serotonin reuptake inhibitor (SSRI) treatment for depression. Differential diagnosis between treatment-resistant depression and SSRI-induced apathy syndrome was required. The symptoms of her apathy syndrome were relieved after the discontinuation of SSRIs and the addition of olanzapine, methylphenidate, and modafinil. Furthermore, we briefly review related literature in this article.
Abstract
There is considerable overlap in the clinical presentations of apathy and depression. However, differential diagnosis between apathy and other psychiatric conditions, including depression and dementia, is important. In this report, we present the case of a 67-year-old woman with a history of receiving selective serotonin reuptake inhibitor (SSRI) treatment for depression. Differential diagnosis between treatment-resistant depression and SSRI-induced apathy syndrome was required. The symptoms of her apathy syndrome were relieved after the discontinuation of SSRIs and the addition of olanzapine, methylphenidate, and modafinil. Furthermore, we briefly review related literature in this article.
참고문헌 (20)
- Marin RS, "Apathy: a neuropsychiatric syndrome", J Neuropsychiatry Clin Neurosci, 3, pp.243~254 (1991)
- Barnhart WJ, "SSRI-induced apathy syndrome:a clinical review", J Psychiatr Pract, 10, pp.196~199 (2004)
- Starkstein SE, "A prospective longitudinal study of apathy in Alzheimer's disease", J Neurol Neurosurg Psychiatry, 77, pp.8~11 (2006)
- Padala PR, "Modafinil therapy for apathy in an elderly patient", Ann Pharmacother, 41, pp.346~349 (2007)
- Roth RM, "Apathy and its treatment", Curr Treat Options Neurol, 9, pp.363~370 (2007)
- McPherson S, "Apathy and executive function in Alzheimer's disease", J Int Neuropsychol Soc, 8, pp.373~381 (2002)
- Wongpakaran N, "Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study", Ann Gen Psychiatry, 6, pp.7~ (2007)
- Dubini A, "Do noradrenaline and serotonin differentially affect social motivation and behaviour?", Eur Neuropsychopharmacol, 7(Suppl 1), pp.S49~S55 (1997)
- Lanctôt KL, "Apathy associated with neurocognitive disorders:Recent progress and future directions", Alzheimers Dement, 13, pp.84~100 (2017)
- Galynker I, "Methylphenidate treatment of negative symptoms in patients with dementia", J Neuropsychiatry Clin Neurosci, 9, pp.231~239 (1997)
- van Reekum R, "N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury", Brain Inj, 9, pp.49~53 (1995)
- Marin RS, "Apathy: a treat-able syndrome", J Neuropsychiatry Clin Neurosci, 7, pp.23~30 (1995)
- Debette S, "Levodopa and bromocriptine in hypoxic brain injury", J Neurol, 249, pp.1678~1682 (2002)
- Newburn G, "Selegiline in the management of apathy following traumatic brain injury", Brain Inj, 19, pp.149~154 (2005)
- Corcoran C, "Bupropion in the management of apathy", J Psychopharmacol, 18, pp.133~135 (2004)
- Holmes C, "The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease", Neurology, 63, pp.214~219 (2004)
- Zhang N, "The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer's disease patients", Dement Geriatr Cogn Disord, 40, pp.85~93 (2015)
- Gerrard P, "Mechanisms of modafinil: a review of current research", Neuropsychiatr Dis Treat, 3, pp.349~364 (2007)
- Camargos EF, "Apathy syndrome treated successfully with modafinil", BMJ Case Rep, 2011, pp.bcr0820114~ (2011)
- Marangell LB, "Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors:an open-label, flexible-dose study", J Clin Psychiatry, 63, pp.391~395 (2002)